John Overdeck’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.5M Buy
182,894
+17,225
+10% +$1.57M 0.01% 1142
2026
Q1
$15.9M Buy
165,669
+100,755
+155% +$10.1M 0.01% 1100
2025
Q4
$6.31M Buy
64,914
+11,267
+21% +$967K 0.01% 1501
2025
Q3
$3.82M Buy
53,647
+13,417
+33% +$894K 0.01% 1677
2025
Q2
$2.41M Buy
40,230
+21,223
+112% +$1.16M ﹤0.01% 1703
2025
Q1
$997K Buy
19,007
+509
+3% +$28.6K ﹤0.01% 2177
2024
Q4
$1.02M Sell
18,498
-21,924
-54% -$1.15M ﹤0.01% 2166
2024
Q3
$2.03M Buy
40,422
+519
+1% +$23.9K ﹤0.01% 1672
2024
Q2
$1.75M Buy
39,903
+8,710
+28% +$370K ﹤0.01% 1636
2024
Q1
$1.37M Buy
31,193
+137
+0.4% +$6.05K ﹤0.01% 1750
2023
Q4
$1.47M Sell
31,056
-5,800
-16% -$244K ﹤0.01% 1830
2023
Q3
$1.64M Buy
36,856
+7,336
+25% +$341K ﹤0.01% 1562
2023
Q2
$1.41M Buy
29,520
+17,205
+140% +$776K ﹤0.01% 1734
2023
Q1
$485K Buy
+12,315
New +$448K ﹤0.01% 2220
2022
Q1
Sell
-13,760
Closed -$636K 3457
2021
Q4
$636K Buy
13,760
+1,509
+12% +$60.9K ﹤0.01% 3011
2021
Q3
$412K Buy
+12,251
New +$417K ﹤0.01% 3425
2020
Q3
Sell
-15,494
Closed -$360K 3305
2020
Q2
$360K Buy
+15,494
New +$333K ﹤0.01% 2251

Other funds holding IRMD

John Overdeck's IRMD Position: Q2 2026 in Review

John Overdeck increased its iRadimed (IRMD) stake by 10% in Q2 2026, buying an estimated $1.57M and bringing the position to 182,894 shares worth $17.5M. The position accounts for 0.01% of the portfolio, ranked #1142.

John Overdeck first reported a position in IRMD in Q2 2020 and has held it in 17 quarters since. 213 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • John Overdeck held 182,894 shares of iRadimed worth $17.5M as of Q2 2026.
  • John Overdeck bought 17,225 iRadimed shares in Q2 2026, an estimated $1.57M.
  • iRadimed made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1142 holding.
  • John Overdeck first reported a position in iRadimed in Q2 2020 and has held it in 17 quarters since.
  • 213 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.